Pleural sarcomatoid mesothelioma: clinical-pathological and survival analysis of a series of 80 cases, multicentre retrospective study


https://doi.org/10.4081/wpph.2015.6707
Vol. 4 (2015)
Submitted: 11 July 2016
Accepted: 11 July 2016
Published: 15 June 2015
mesotelioma pleurico sarcomatoide, studio retrospettivo
Abstract Views: 579
PDF: 8595
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

  • G. Gallizzi Unità Funzionale Interaziendale Mesotelioma – S.C. Oncologia ASO SS Antonio e Biagio e C. Arrigo, Alessandria, Italy.
  • S. Crivellari Unità Funzionale Interaziendale Mesotelioma – S.C. Oncologia ASO SS Antonio e Biagio e C. Arrigo, Alessandria, Italy.
  • A. Roveta Unità Funzionale Interaziendale Mesotelioma – S.C. Oncologia ASO SS Antonio e Biagio e C. Arrigo, Alessandria, Italy.
  • A. Muzio S.O.C. Oncologia ASO SS Antonio e Biagio e C. Arrigo, Alessandria, Italy.
  • S. Zai Unità Funzionale Interaziendale Mesotelioma – S.C. Oncologia ASO SS Antonio e Biagio e C. Arrigo, Alessandria, Italy.
  • G. Taverna S.O.C. Radiologia ASO SS Antonio e Biagio e C. Arrigo, Alessandria, Italy.
  • A. Aurelio S.O.C. Radiologia ASO SS Antonio e Biagio e C. Arrigo, Alessandria, Italy.
  • R. Libener S.C. Anatomia Patologica ASO SS Antonio e Biagio e C. Arrigo, Alessandria, Italy.
  • N. Mariani S.C. Anatomia Patologica ASO SS Antonio e Biagio e C. Arrigo, Alessandria, Italy.
  • M. D’Angelo Centro Sanitario Regionale Amianto ASL AL Ospedale Santo Spirito, Casale Monferrato, Italy.
  • D. Degiovanni Hospice Monsignor Zaccheo ASL AL, Casale Monferrato, Italy.
  • F. Grosso
    fgrosso@ospedale.al.it
    Unità Funzionale Interaziendale Mesotelioma – S.C. Oncologia ASO SS Antonio e Biagio e C. Arrigo, Alessandria, Italy.

Introduction: Malignant pleural mesothelioma is a rare disease, but with a non-negligible incidence in asbestos-polluted areas. The sarcomatoid histotype (SMPM) is characterised by a particularly poor prognosis. Methodology: The characteristics and clinical outcomes of 80 patients with PMMS followed at the hospitals of Alessandria, Casale Monferrato, Rozzano and Padua were analysed. Results: After first-line chemotherapy partial response (PR) was observed in 2 patients (2.5%), disease stability (SD) in 32 patients (40%), disease progression (PD) in 25 patients (31%), non-assessable disease for 21 patients (26%). Time to progression (TTP) was 3.5 months; overall survival (OS) was 7.8 months. OS of patients receiving pemetrexed was 7.5 months vs 8.9 months of patients receiving chemotherapy without pemetrexed (p>0.05). Conclusion: The data confirm that sarcomatoid histotype has a worse prognosis than epithelioid, with poorer survival and poorer response to treatment. In particular, standard chemotherapy did not show efficacy, underlining the need for other therapeutic perspectives in clinical trials focusing on new biomolecular targets.


Gallizzi, G., Crivellari, S., Roveta, A., Muzio, A., Zai, S., Taverna, G., Aurelio, A., Libener, R., Mariani, N., D’Angelo, M., Degiovanni, D., & Grosso, F. (2015). Pleural sarcomatoid mesothelioma: clinical-pathological and survival analysis of a series of 80 cases, multicentre retrospective study. Working Paper of Public Health, 4(1). https://doi.org/10.4081/wpph.2015.6707

PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.

Downloads

Download data is not yet available.

Citations

Crossref
Scopus
Google Scholar
Europe PMC

Most read articles by the same author(s)

1 2 3 > >>